Tumor therapeutic agent
US12220398B2 · kind B2 · utility
0Cited by
108References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2016 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Aug 18, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.